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Abstract
Background: Standard Mendelian randomization analysis can produce biased results if the genetic
variant defining the instrumental variable (IV) is confounded and/or has a horizontal pleiotropic
effect on the outcome of interest not mediated by the treatment.
Development: We provide novel identification conditions for the causal effect of a treatment in
presence of unmeasured confounding, by leveraging an invalid IV for which both the IV indepen-
dence and exclusion restriction assumptions may be violated. The proposed Mendelian Random-
ization Mixed-Scale Treatment Effect Robust Identification (MR MiSTERI) approach relies on (i)
an assumption that the treatment effect does not vary with the invalid IV on the additive scale; and
(ii) that the selection bias due to confounding does not vary with the invalid IV on the odds ratio
scale; and (iii) that the residual variance for the outcome is heteroscedastic and thus varies with
the invalid IV. Although assumptions (i) and (ii) have, respectively appeared in the IV literature,
assumption (iii) has not; we formally establish that their conjunction can identify a causal effect
even with an invalid IV subject to pleiotropy. MiSTERI is shown to be particularly advantageous
in presence of pervasive heterogeneity of pleiotropic effects on additive scale, a setting in which
two recently proposed robust estimation methods MR GxE and MR GENIUS can be severely bi-
ased. For estimation, we propose a simple and consistent three-stage estimator that can be used as
preliminary estimator to a carefully constructed one-step-update estimator, which is guaranteed to
be more efficient under the assumed model. In order to incorporate multiple, possibly correlated
and weak IVs, a common challenge in MR studies, we develop a MAny Weak Invalid Instruments
(MR MaWII MiSTERI) approach for strengthened identification and improved accuracy. We have
developed an R package MR-MiSTERI for public use of all proposed methods.
Application: We illustrate MR MiSTERI in an application using UK Biobank data to evaluate
the causal relationship between body mass index and glucose, thus obtaining inferences that are
robust to unmeasured confounding, leveraging many weak and potentially invalid candidate genetic
IVs.
Conclusion: MaWII MiSTERI is shown to be robust to horizontal pleiotropy, violation of IV
independence assumption and weak IV bias. Both simulation studies and real data analysis results
demonstrate the robustness of the proposed MR MiSTERI methods.
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2
1 Introduction
Mendelian randomization (MR) is an instrumental variable (IV) approach that uses genetic variants,
for example, single-nucleotide polymorphisms (SNPs), to infer the causal effect of a modifiable risk
treatment on a health outcome (Smith and Ebrahim 2003). MR has recently gained popularity
in epidemiological studies because, under certain conditions, it can provide unbiased estimates
of causal effects even in the presence of unmeasured exposure-outcome confounding. For example,
findings from a recent MR analysis assessing the causal relationship between low-density lipoprotein
cholesterol and coronary heart disease (Ference et al. 2017) in an observational study are consistent
with the results of earlier randomized clinical trials (Scandinavian Simvastatin Survival Study
Group 1994).
For a SNP to be a valid IV, it must satisfy the following three core assumptions (Didelez and
Sheehan 2007; Lawlor et al. 2008):
(A1) IV relevance: the SNP must be associated (not necessarily causally) with the exposure;
(A2) IV independence: the SNP must be independent of any unmeasured confounder of the
exposure-outcome relationship;
(A3) Exclusion restriction: the SNP cannot have a direct effect on the outcome variable not
mediated by the treatment , that is, no horizontal pleiotropic effect can be present.
The causal diagram in Figure 1(a) graphically represents the three core assumptions of a valid IV. It
is well-known that even when assumptions (A1)-(A3) hold for a given IV, the average causal effect of
the treatment on the outcome cannot be point identified without an additional condition, the nature
of which dictates the interpretation of the identified causal effect. Specifically, Angrist et al. (1996)
proved that under A1-A3 and a monotonicity assumption about the IV-treatment relationship, the
so-called complier average treatment effect is nonparametrically identified. More recently, Wang
and Tchetgen Tchetgen (2018) established identification of population average causal effect under
(A1)-(A3) and an additional assumption of no unmeasured common effect modifier of the association
between the IV and the endogenous variable, and the treatment causal effect on the outcome. A
special case of this assumption is that the association between the IV and the treatment variable
is constant on the additive scale across values of the unmeasured confounder (Tchetgen Tchetgen
et al. (2020)). In a separate strand of work, Robins (1994) identified the effect of treatment on
the treated under (A1)-(A3) and a so-called no current-treatment value interaction assumption
(A.4a) that the effect of treatment on the treated is constant on the additive scale across values
of the IV. In contrast, Liu et al. (2020) established identification of the ETT under (A1)-(A3),
and an assumption (A.4b) that the selection bias function defined as the odds ratio association
between the potential outcome under no treatment and the treatment variable, is constant across
values of the IV. Note that under the IV DAG Figure 1(a), assumption (A1) is empirically testable
while (A2) and (A3) cannot be refuted empirically without a different assumption being imposed
(Glymour et al. 2012). Possible violation or near violation of assumption (A1) known as the weak
IV problem poses an important challenge in MR studies as the associations between a single SNP
IV and complex traits can be fairly weak (Staiger and Stock 1997; Stock et al. 2002). But massive
genotyped datasets have provided many such weak IVs. This has motivated a rich body of work
addressing the weak IV problem under a many weak instruments framework,from a generalized
method of moments perspective given individual level data (Chao and Swanson 2005; Newey and
Windmeijer 2009; Davies et al. 2015), and also from a summary-data perspective (Zhao et al.
2019a,b; Ye et al. 2019). Violation of assumption (A2) can occur due to population stratification,
or when selected SNP IV is in linkage disequilibrium (LD) with another genetic variant which has
a direct effect on the outcome (Didelez and Sheehan 2007). Violations of (A3) can occur when
the chosen SNP IV has a non-null direct effect on the outcome not mediated by the exposure,
commonly referred to as horizontal pleiotropy and is found to be widespread (Solovieff et al. 2013;
Verbanck et al. 2018). A standard MR analysis (i.e. based on standard IV methods such as 2SLS)
with an invalid IV that violates any of those three core assumptions might yield biased causal effect
estimates.
Methods to address possible violations of (A2) or (A3) given a single candidate IV are limited.
Two methods have recently emerged as potentially robust against such violation under certain
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Figure 1: Directed acyclic graph (DAG) with an instrument (Z), an outcome (Y ), a treatment(A)
and unmeasured confounders (U). The left panel shows a valid Mendelian randomization study and
the right panel shows violations of IV independence and exclusion restriction assumptions.
conditions. The first, known as MR-GxE, assumes that one has observed an environmental factor,
which interacts with the invalid IV in its additive effects on the treatmentof interest, and that such
interaction is both independent of any unmeasured confounder of the exposure-outcome relation-
ship, and does not operate on the outcome in view (Spiller et al. 2019, 2020). In other words,
MR-GxE essentially assumes that while the candidate SNP may not be a valid IV, its additive
interaction with an observed covariate constitutes a valid IV which satisfies (A1-A3). In contrast,
MR GENIUS relies on an assumption that the residual variance of the first stage regression of the
treatmenton the candidate IV is heteroscedastic with respect to the candidate IV, i.e. the variance
of the treatment depends on the IV, an assumption that may be viewed as strengthening of the IV
relevance assumption (Tchetgen Tchetgen et al. 2020). Interestingly, as noted by Tchetgen Tch-
etgen et al. (2020), existence of a GxE interaction that satisfies conditions (A1-A3) required by
MR GxE had such an E variable (independent of G) been observed, necessarily implies that the
heteroscedasticity condition required by MR GENIUS holds even when the relevant E variable is
not directly observed. Furthermore, as it is logically possible for heteroscedasticity of the variance
of the treatment to operate even in absence of any GxE interaction, MR GENIUS can be valid in
certain settings where MR GxE is not.
In this paper, we develop an alternative robust MR approach to estimating a causal effect of
a treatment subject to unmeasured confounding, leveraging a potentially invalid IV which fails
to fulfil either IV independence or exclusion restriction assumptions. The proposed Mendelian
Randomization Mixed-Scale Treatment Effect Robust Identification (MR MiSTERI) approach relies
on (i) an assumption that the treatment effect does not vary with the invalid IV on the additive
scale; and (ii) that the selection bias due to confounding does not vary with the invalid IV on the
odds ratio scale; and (iii) that the residual variance for the outcome is heteroscedastic and thus
varies with the invalid IV. Although assumptions (i) and (ii) have, respectively appeared in the
IV literature, assumption (iii) has not; we formally establish that their conjunction can identify a
causal effect even with an invalid IV subject to pleiotropy. MiSTERI is shown to be particularly
advantageous in presence of pervasive heterogeneity of pleiotropic effects on the additive scale, a
setting in which both MR GxE and MR GENIUS can be severely biased whenever heteroscedastic
first stage residuals can fully be attributed to latent heterogeneity in SNP-treatment association
(cite GDS group recent paper comparing the methods). For estimation, we propose a simple and
consistent three-stage estimator that can be used as preliminary estimator to a carefully constructed
one-step-update estimator, which is guaranteed to be more efficient under the assumed model. In
order to incorporate multiple, possibly correlated and weak IVs, a common challenge in MR studies,
we develop a MAny Weak Invalid Instruments (MaWII MR MiSTERI) approach for strengthened
identification and improved accuracy. Simulation study results show that our proposed MR method
give consistent estimates of the causal parameter and the selection bias parameter with nominal
confidence interval coverage with an invalid IV, and the accuracy is further improved with multiple
weak invalid IVs. For illustration, we apply our method to the UK Biobank data set to estimate
the causal effect of body mass index (BMI) on average glucose level.
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2 Methods
2.1 Identification with a Binary treatment and a Possibly Invalid Binary
IV
Suppose that we observe data Oi = (Zi, Ai, Yi) of size n drawn independently from a common
population, where Zi, Ai, Yi denote a SNP IV, a modifiable treatment and a continuous outcome
of interest for the ith subject (1 ≤ i ≤ n), respectively. In order to simplify the presentation, we
drop the sample index i and do not consider observed covariates at this stage, although all the
conclusions continue to hold within strata defined by observed covariates. Let z, a, y denote the
possible values that Z,A, Y could take, respectively. Let Yaz denote the potential outcome, had
possibly contrary to fact, A and Z been set to a and z respectively, and let Ya denote the potential
outcome had A been set to a. We are interested in estimating the ETT defined as
β(a) = E(Ya − Y0 | A = a)
To facilitate the exposition, consider the simple setting where both the treatment and the SNP
IV are binary, then the ETT simplifies to β = E(Y1 − Y0 | A = 1). By the consistency assumption,
we know that E(Y1 | A = 1) = E(Y | A = 1). However, the expectation of the potential outcome
Y0 among the exposed subpopulation E(Y0 | A = 1) cannot empirically be observed due to possible
unmeasured confounding for the exposure-outcome relationship. The following difference captures
this confounding bias on the additive scale Bias = E(Y0 | A = 1) − E(Y0 | A = 0), which is
exactly zero only when exposed and unexposed groups are exchangeable on average (i.e. under no
confounding) (Hernan and Robins 2020), and is otherwise not null. With this representation and
the consistency assumption, we have
E(Y | A = 1)− E(Y | A = 0) = β +Bias.
This simple equation implies that one can only estimate the sum of the causal effect β and the
confounding bias but cannot tease them apart using the data (A, Y ) only. With the availability of
a binary candidate SNP IV Z that is possibly invalid, we can further stratify the population by Z
to obtain under consistency:
E(Y | A = 1, Z = z)− E(Y | A = 0, Z = z) = β(z) +Bias(z),
where z is equal to either 0 or 1, and β(z) = E(Ya − Y0 | A = a, Z = z), Bias(z) = E(Y0 | A =
1, Z = z)−E(Y0 | A = 0, Z = z) denote the causal effect and bias in the stratified population with
the IV taking value z. Note that there are only two equations but four unknown parameters: β(z),
Bias(z), z = 0, 1. Therefore, the causal effect cannot be identified without imposing assumptions
to reduce the total number of parameters to two.
Our first assumption extends Robins (1994) no current-treatment value interaction assumption
(A.4a), that the causal effect does not vary across the levels of the SNP IV so that β(z) is a constant
as function of z. Formally stated:
(B1) Homogeneous ETT assumption: E(Ya=1,z − Ya=0,z | A = 1, Z = z) = β.
It is important to note that this assumption does not imply the exclusion restriction assumption
(A3); it is perfectly compatible with presence of a direct effect of Z on Y (the direct arrow from
Z to Y is present in Figure 1(b)), i.e. E(Ya=0,z=1 − Ya=0,z=0 | A = 1, Z = z) 6= 0, which we
accommodate.
In order to state our second core assumption, consider the following data generating mecha-
nism for the treatment, which encodes presence of unmeasured confounding by making dependence
between A and Y0 explicit under a logistic model:
logit {Pr(A = 1 | Y0 = y0, Z = z)} = γ0 + γy0 + γzz + γy0zy0z.
This model can of course not be estimated directly from the observed data without any ad-
ditional assumption because it would require the potential outcome Y0 be observed both on the
untreated (guaranteed by consistency) and the treated. Nevertheless, this model implies that the
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conditional (on Z) association between A and Y0 on the odds ratio scale is OR(Y0 = y0, A = 1 |
Z = z) = exp(γy0 + γy0zy0z).
Together, γ and γy0z encode the selection bias due to unmeasured confounding on the log-odds
ratio scale. If both γ and γy0z are zeros, then A and Y0 are conditionally (on Z) independent, or
equivalently, there is no residual confounding bias upon conditioning on Z. Our second identifying
assumption formally encodes assumption A4.b of Liu et al. (2020) of homogeneous odds ratio
selection bias γy0z = 0:
(B2) Homogeneous selection bias: OR(Y0 = y0, A = a | Z = z) = exp(γay0).
Assumption (B2) states that the selection bias on the odds ratio scale is homogeneous across levels
of the IV. Thus, this assumption allows for the presence of unmeasured confounding which, upon
setting γy0z = 0 is assumed to be on average balanced with respect to the SNP IV (on the odds
ratio scale). Following Liu et al. (2020), we have that under (B2)
E(Y0 | A = a, Z = z) = E{Y exp(γaY ) | A = 0, Z = z}
E{exp(γaY ) | A = 0, Z = z}
Define ε = Y − E(Y | A,Z), and suppose that ε | A,Z ∼ N(0, σ2(Z)), then after some algebra we
have,
E(Y0 | A = 1, Z = z) = E(Y | A = 0, Z = z) + γσ2(Z).
The selection bias on the odds ratio scale does not vary with the levels of the IV, however in order
to achieve identification, the bias term γσ2(Z) must depend on the IV. This observation motivates
our third assumption,
(B3) Heteroscedasticity, that is σ2(Z) cannot be a constant.
Assumption (B3) is empirically testable using existing statistical methods for detecting non-constant
variance in regression models. For example, the Levene test has been used in genetic association
studies and found several SNPs associated with the variance of several phenotypes. The well-known
FTO variant (rs7202116) was found to be associated with the phenotypic variability of body mass
index (BMI) (P=2.4E-10; N=131233) by using a two-stage procedure (Yang et al. 2012). They
first regress BMI on the SNP genotype, then regress the squared residuals on the SNP genotype
again to test for association of the SNP with the variance of BMI. Previous large-scale genetic
association studies show that our assumption (B3) is scientifically plausible. Furthermore, one can
generally expect the assumption to hold in presence of pervasive heterogeneity of pleiotropic effects
on additive scale for the outcome, a setting in which both MR GxE and MR GENIUS can be
severely biased. Under assumptions (B1) -(B3), we have
E(Y | A = 1, Z = z)− E(Y | A = 0, Z = z) = β + γσ2(z).
Note that σ2(z) is the variance of Y given z, and thus can be estimated with no bias. For the
binary IV Z, σ2(Z = 0) and σ2(Z = 1) are the variance of Y within each IV stratum and can easily
be estimated using the sample variance in each group. We will describe estimating procedures in
the next section for more general settings where Z is not necessarily binary. Importantly, in the
present case, we now have two equations and two unknown parameters β, γ.
Denote D(Z = z) = E(Y | A = 1, Z = z) − E(Y | A = 0, Z = z). Therefore we have the
following main identification result.
Theorem 1. Under assumptions (B1)-(B3), the selection bias parameter and the causal effect of
interest are uniquely identified as followed:
γ =
D(Z = 1)−D(Z = 0)
σ2(Z = 1)− σ2(Z = 0)
β = E{D(Z)− D(Z = 1)−D(Z = 0)
σ2(Z = 1)− σ2(Z = 0)σ
2(Z)}
= D(z)− D(Z = 1)−D(Z = 0)
σ2(Z = 1)− σ2(Z = 0)σ
2(z); z = 0, 1.
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Figure 2: An illustration of our identification strategy for a binary treatment A and binary IV Z. The
green line represents E(Y | A = 0, Z = z) and its difference between Z = 1 and Z = 0 is θz. The red
dashed line (parallel to the green line) represents the hypothetical setting when σ2(Z = z) is constant,
and the red solid line represents the setting when σ2(Z = z) is not a constant function in Z. Note
that b0 and b are treated as known.
In an observed sample, one can simply use the sample versions of unknown quantities to obtain
estimates for β and γ. Standard errors can be deduced by a standard application of the multivariate
delta method, or by using resampling techniques such as the jacknife or the bootstrap.
Remark 1. Note that as stated in the theorem, the causal parameter β can be estimated based
on data among either Z = 0 or Z = 1 group. In practical settings, in order to improve efficiency,
one may take either unweighted average of the two estimates as given in the theorem, or their
inverse variance weighted average. In fact, one may fit a saturated linear model for the variance
σ2(Z = z) = b0 + bz; We give a graphical illustration of our identification condition as shown
in Figure 2. By using the heteroscedasticity assumption (B3), we can identify the selection bias
parameter γ and then the causal effect parameter β. Without the assumption (B3) as shown by
the red dashed line, we can only obtain β + γb0 and thus cannot tease apart the causal effect and
the selection bias.
2.2 Identification with a Continuous treatment and a Possibly Invalid
Discrete IV
The identification strategy in the previous section extends to the more general setting of continuous
treatment and a more general discrete IV, for example, the SNP IV taking values 0, 1, 2 correspond-
ing to number of minor alleles. To do so requires we introduce the notion of generalized conditional
odds ratio function as a measure the conditional association between a continuous treatment and a
continuous outcome. To ground idea, consider the following model for the treatment free potential
outcome:
Y0 = E(Y0|A,Z) + σ(Z)
where  is independent standard normal; then one can show that the generalized conditional odds
ratio function associated with Y0 and A given Z with (Y0 = 0, A = 0) taken as reference values
Chen (2007) is given by
OR(y0, a | z) = f(y0 | a, z)f(y0 = 0 | a = 0, z)
f(y0 | a = 0, z)f(y0 = 0 | a, z) = exp{(E(Y0|A = a, Z)−E(Y0|A = 0, Z))y0/σ
2(Z)}
which by Assumption (B2) implies that E(Y0|A,Z) − E(Y0|A = 0, Z) = γσ2(Z)A. We therefore
have
µ(a, z) = E(Y | A = a, Z = z) = βa+ γσ2(Z = z)a+ E(Y | A = 0, Z = z).
7
For practical interpretation, we assume A has been centered so that A = 0 actually represents
average treatment value in the study population. Assume the following model E(Y | A = 0, Z =
z) = θ0 + θzz and a log linear model for σ
2(Z) such that
µ(a, z) = βA+ γAσ2(Z) + θ0 + θzZ
log(σ2(Z)) = η0 + ηzZ.
The conditional distribution of Y given A and Z is
Y | A = a, Z = z ∼ N (µ(a, z), σ2(z))
Then we can simply use standard maximum likelihood estimation (MLE) to obtain consistent and
fully efficient estimates for all parameters under the assumed model. However, the likelihood may
not be log-concave and direct maximization of the likelihood function with respect to all parameters
might not always converge. Instead, we propose a novel three-stage estimation procedure which
can provide a consistent but inefficient preliminary estimator of unknown parameters. We then
propose a carefully constructed one-step update estimator to obtain a consistent and fully efficient
estimator. Our three-stage estimation method works as follows.
Stage 1 Fit the following linear regression using standard (weighted) least-squares
Y = θ0 + θaA+ θzZ + θazAZ + ε.
We obtain parameter estimates θˆ0, θˆa, θˆz, θˆaz, Eˆ(Y | A = 0, Z) = θˆ0 + θˆzZ, with corresponding
estimated residuals εˆ = Y − θˆ0 − θˆaA− θˆzZ − θˆazAZ.
Stage 2 Regress the squared residuals εˆ2 on (1, Z) in a log-linear model and obtain parameter
estimates ηˆ0, ηˆz and σˆ
2(Z) = exp(ηˆ0 + ηˆzZ).
Stage 3 Regress Y − Eˆ(Y | A = 0, Z) on A and Aσˆ2(Z) without an intercept term and obtain the
two corresponding regression coefficients estimates βˆ and γˆ respectively.
Alternatively, we may also fit E(Y | A,Z) = βA+ γAσˆ2(Z) + θ0 + θzZ in Stage 3.
The proposed three-stage estimation procedure is computationally convenient, appears to always
converge and provides a consistent estimator for all parameters under the assumed model. Next we
propose the following one-step update to obtain a fully efficient estimator. Consider the following
normal model
Y − {βA+ γA exp(η0 + ηzZ) + θ0 + θzZ}√
exp(η0 + ηzZ)
∼ N(0, 1). (1)
Denote Θ = (β, γ, η0, ηz, θ0, θz) and denote the log-likelihood function as l(Θ;Y,A,Z) for an indi-
vidual. With a sample of size n, the log-likelihood function is
ln(Θ) =
n∑
i=1
li(Θ;Yi, Ai, Zi).
The score function Sn(Θ) = ∂ln(Θ)/∂Θ is defined as the first order derivative of the log-likelihood
function with respect to Θ, and use in(Θ) = ∂
2ln(Θ)/∂Θ∂Θ
T to denote the second order derivative
of the log-likelihood function. Suppose we have obtained a consistent estimator Θ˜(0) of Θ using the
three-stage estimating procedure, then one can show that a consistent and fully efficient estimator
is given by the one-step update estimator Θ˜
Θ˜ = Θ˜− {in(Θ˜(0))}−1Sn(Θ˜(0))). (2)
Remark 2. In biomedical studies, continuous outcomes of interest are often approximately nor-
mally distributed, and the normal linear regression is also routinely used by applied researchers.
When the normal assumption is violated, a typical remedy is to apply a transformation to the
outcome prior to modeling it, such as the log-transformation or the more general Box-Cox trans-
formation to achieve approximate normality. Alternatively, below we propose to model the error
distribution as a more flexible Gaussian mixture model which is more robust than the Gaussian
model. Alternatively, as described in the Supplemental materials, one may consider a semipara-
metric location-scale model which allows the distribution of standardized residuals to remain un-
restricted, a potential more robust approach although computationally more demanding.
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2.3 Estimation and Inference under Many Weak Invalid IVs
Weak identification bias is a salient issue that needs special attention when using genetic data to
strengthen causal inference, as most genetic variants are only weakly associated with the traits.
When many genetic variants are available, we recommend using the conditional maximum like-
lihood estimator (CMLE) based on (1), where Z is replaced with a multi-dimensional vector. Let
Θˆ be the solution to the corresponding score functions, i.e., Sn(Θˆ) = 0; let
I1(Θ) = −E
{
∂2
∂Θ∂ΘT
l1(Θ, Y1, A1, Z1)
}
be the Fisher information matrix based on the conditional likelihood function for one observation.
Let k be the total number of parameters in Θ, which is equal to 4 + 2p when Z is p dimensional.
When λmin{nI1(Θ)}/k →∞ with λmin{nI1(Θ)} being the minimum eigenvalue of nI1(Θ), we show
in the supplementary materials (Theorem 3) that Θˆ is consistent and asymptotically normal as the
sample size goes to infinity, and satisfies
√
n(Θˆ−Θ) d−→ N(0, {I1(Θ)}−1). (3)
In other words, the CMLE is robust to weak identification bias and the usual inference procedure
can be directly applied.
The key condition λmin{nI1(Θ)}/k → ∞ warrants more discussion. Note that the quantity
λmin{nI1(Θ)}/k measures the ratio between the amount of information that a sample of size n
carries about the unknown parameter and the number of parameters. In classic strong identification
scenarios where the minimum eigenvalue of I1(Θ) is assumed to be lower bounded by a constant,
then the condition simplifies to that the number of parameter is small compared with the sample
size, i.e., n/k →∞. However, when identification is weak, the minimum eigenvalue of I1(Θ) can be
small. In practice, the condition λmin{nI1(Θ)}/k →∞ can be evaluated by κˆ = −λmin{in(Θˆ)}/k,
which is the ratio between the minimum eigenvalue of the negative Hessian matrix and the number
of parameters. We remark that the condition stated in the supplementary materials (Theorem 3)
is more general and applies to general likelihood-based methods, which, for example, implies the
condition for consistency for the profile likelihood estimator (MR.raps) in Zhao et al. (2019b).
For valid statistical inference, a consistent estimator for the variance covariance matrix for Θˆ is
simply the negative Hessian matrix −in(Θˆ), whose corresponding diagonal element estimates the
variance of the treatment effect estimator βˆ. Other variants of the CMLE can also be used, for
example, the one-step iteration estimator Θ˜ in (2) is asymptotically equivalent with the CMLE Θˆ
as long as the initial estimator Θ˜(0) is
√
n-consistent (Shao 2003).
2.4 Gaussian mixture model
Consider the general location-scale model
Y = E(Y |A,Z) + σ(Z),
where  ⊥ A,Z. Under assumptions (B1)-(B3), the conditional mean function is given by
E (Y |A = a, Z = z) = βa+ E (Y |A = 0, Z = z) + ∂
∂(γa)
ln
∫
exp [γaσ (Z = z) ] dF () ,
where F (·) denotes the cumulative distribution function of . The error distribution may be rea-
sonably approximated by a Gaussian mixture model with enough components (Goodfellow et al.
2016). Specifically, let f() =
∑K
k=1 pikφk() where φk(·) is the normal density with mean µk and
variance δ2k satisfying the constraints
K∑
k=1
pik = 1, E() =
K∑
k=1
pikµk = 0, Var () =
K∑
k=1
pik
(
δ2k + µ
2
k
)
= 1.
The conditional mean function with Gaussian mixture error is given by
βa+ E (Y |A = 0, Z = z) + σ (Z = z)∑K
k=1 pikωk
{[
K∑
k=1
pikωkµk
]}
+ γa
K∑
k=1
pikωkδ
2
kσ
2 (Z = z)∑K
k=1 pikωk
,
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Table 1: Simulation results for estimating the confounding bias parameter γ and the ETT β using the
one-step estimator approach (without covariates) based on 1000 Monte Carlo experiments with a range
of sample sizes n. γˆ is the averaged point estimates of γ, and bias is calculated in percentage format.
Likewise for βˆ. SE is the averaged standard error. SD stands for the sample standard deviation of the
1000 point estimates for γ and β. Coverage is calculated as the proportion of 95% confidence intervals
that contains the true parameter value among those 1000 experiments. We vary the value of ηz in
σ2(Z) = exp(η0 + ηzZ)) to assess the impact of decreasing IV strength on the estimation results.
n ηz (β, γ) βˆ Bias SE SD Cover γˆ Bias SE SD Cover
1e4 0.2 (0.8,0.2) 0.806 0.74 % 0.092 0.094 93.8% 0.196 -2.12% 0.074 0.075 94.6%
1e4 0.15 (0.8,0.2) 0.788 -1.44% 0.124 0.126 95.6% 0.210 4.77 % 0.103 0.104 95.6%
1e4 0.1 (0.8,0.2) 0.778 -2.76% 0.197 0.210 96.2% 0.219 9.32% 0.168 0.181 96.0%
3e4 0.1 (0.8,0.2) 0.789 -1.35% 0.104 0.106 96.0% 0.209 4.58 % 0.089 0.090 95.8%
3e4 0.05 (0.8,0.2) 0.788 -1.46% 0.226 0.222 97.0% 0.210 5.17% 0.199 0.195 97.4%
1e5 0.05 (0.8,0.2) 0.797 -0.36% 0.113 0.120 95.2% 0.203 1.29% 0.099 0.105 95.2%
where ωk = exp
(
γaσ (Z = z)µk + δ
2
k [γaσ (Z = z)]
2
/2
)
. The conditional distribution is {Y −
E (Y |A = a, Z = z)}/σ (Z = z) ∼∑Kk=1 pikN(µk, δ2k). In practice, estimation of (β, γ) may proceed
under a user-specified integer value K < ∞ as well as parametric models for E(Y |A = 0, Z = z)
and σ(Z = z) via an alternating optimization algorithm which we describe in the Supplementary
Materials.
3 Simulation Studies
In this section, we conduct simulation studies to evaluate the finite-sample performance of our one-
step-update estimating method. Sample sizes of n = 10, 000, 30, 000, 100, 000 are considered; still
considerably smaller than the UK Biobank study considered below for illustration with sample size
of a couple of hundred thousands independent samples. If our method can produce good estimates
in smaller sample settings, we expect it will have even better performance in larger sample settings.
The IV Z is generated from a Binomial distribution with probability equal to 0.3 (minor allele
frequency). The treatment A is simply generated from the standard normal distribution N(0, 1).
The outcome Y is also generated from a normal distribution with mean and variance given by
E(Y | A,Z) = 0.8A+ 0.2Aσ2(Z) + 1 + 0.3Z
σ2(Z) = exp(0.1 + ηzZ)
where ηz is set to be 0.2, 0.15, 0.1, 0.05. We generated in total 1000 such data sets and then apply
our proposed CMLE to each of them. Results are summarized in Table 1. We found that when
sample size is 10,000, the bias and standard error of the causal effect and selection bias parameter
estimates become larger when the IV strength ηz decreases from 0.2 to 0.1. The causal effect is less
sensitive to the IV strength compared to the selection bias parameter γ. As we increase sample
size, the bias gets much smaller and becomes negligible when the sample size is 100,000. Confidence
intervals achieved the nominal 95% coverage.
The second simulation study is designed to evaluate the finite sample performance of the pro-
posed three-stage estimator and the CMLE in presence of many weak invalid IVs. The sample size
is set to be 100,000, each IV Zj , j = 1, . . . , p, is still generated to take values 0,1,2 with minor allele
frequency equal to 0.3. The treatment A is generated from standard normal distribution. The
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outcome Y is generated from a normal distribution with mean and variance given by
E(Y | A,Z) = 0.8A+ 0.2Aσ2(Z)− 0.5 + 0.5
p∑
j=1
Zj ,
σ2(Z) = exp
0.1 + 0.05 p∑
j=1
Zj
 .
Simulation results are presented in Table 2, where the standard error (SE) for the three-stage
estimator is the bootstrap estimator approximated using 100 Monte Carlo simulations, the SE for
the CMLE is obtained from the inverse Hessian matrix discussed in Section 2.3. From the results in
Table 2, the three-stage estimator has negligible bias when p = 20, but shows evidently larger bias
when p grows to 50, which is also reflected by the fact that the coverage probabilities are smaller
than 95%. In contrast, the CMLE shows negligible bias in both scenarios. The standard errors for
the CMLE are close to the standard deviations, and the CMLE estimators show nominal coverage
in both simulation scenarios.
These observations agree with our theoretical assessment that the CMLE is efficient and is
robust to many weak invalid IVs. In particular, it is consistent and asymptotically normal as long
as the condition κˆ is reasonable large.
3.1 Simulation under Gaussian mixture error
We similarly generate the treatment A from the standard normal distribution, the IV Z which takes
values in {0, 1, 2} with minor allele frequency equal to 0.3. However we generate Y = E(Y |A,Z) +
σ(Z) where the error  is generated from a Gaussian mixture distribution with two components,
ε1 ∼ N(µ1, δ21), ε2 ∼ N(µ2, δ22), pi1 ∼ Bernoulli(p = 0.4), pi2 = 1− pi1,  = pi1ε1 + pi2ε2,
(µ1, µ2) = (−0.6, 0.4) and (δ1, δ2) = (0.5, 1.049), and
E(Y | A,Z) = 0.8A+ (1 + 0.3Z) + σ(Z)
{∑2
k=1 pikωk
[
µk + δ
2
kγAσ (Z)
]∑2
k=1 pikωk
}
,
σ2(Z) = exp(0.1 + ηzZ).
We vary the value of ηz in the set {0.1, 0.25, 0.5} to assess the impact of IV strength. The results
using the proposed Gaussian mixture method with K = 2 are summarized in Table 3. There is
noticeable finite-sample bias and under-coverage when ηz = 0.1, especially for estimation of the
selection bias parameter γ, but the performance improves with larger ηz or sample size. We perform
an additional set of simulations to assess the impact of model misspecification. Specifically, the
error is generated from a mixture of two uniform distributions
ε1 ∼ U(a1, b1), ε2 ∼ U(a2, b2), pi1 ∼ Bernoulli(p = 0.4), pi2 = 1− pi1,  = pi1ε1 + pi2ε2,
where (a1, b1) = (0.6− 0.87, 0.6 + 0.87) and (a2, b2) = (0.4− 1.82, 0.4 + 0.82). To be consistent with
the implications of assumptions (B1)-(B3), we then generate the outcome with
E(Y | A,Z) = 0.8A+ (1 + 0.3Z)
+ σ(Z)
[∑2
k=1 pik{(bkt− 1) exp(bkt)− (akt− 1) exp(akt)}/{t2(bk − ak)}∑2
k=1 pik{exp(bkt)− exp(akt)}/{t(bk − ak)}
]
,
σ2(Z) = exp(0.1 + ηzZ);
where t(A,Z; γ) ≡ γAσ(Z). The Gaussian mixture procedure with K = 2 failed to converge in the
weak IV setting where ηz = 0.1; we only report results for ηz = 0.25 or 0.5 in Table 4. The absolute
bias of the Gaussian mixture estimator becomes noticeably larger for the same values of (n, ηz),
especially in estimation of γ. The average standard error at ηz = 0.25 is significantly larger than
the Monte Carlo standard error, resulting in somewhat conservative confidence intervals. Although
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Table 2: Simulation results for estimating the confounding bias parameter γ = 0.2 and the ETT
β = 0.8 using the three-stage estimator and the CMLE based on 1000 Monte Carlo experiments, with
n = 100, 000 and varying p. The third column is the averaged κˆ = −λmin{in(Θˆ)}/k, which is the
consistency and asymptotic normality condition for the CMLE and is preferably to be large. γˆ is the
averaged point estimates of γ, and bias is calculated in percentage format. Likewise for βˆ. SE is the
averaged standard error. SD stands for the sample standard deviation of the 1000 point estimates for
γ and β. Coverage is calculated as the proportion of 95% confidence intervals that contains the true
parameter value among those 1000 experiments.
n p κˆ Method βˆ Bias SE SD Cover γˆ Bias SE SD Cover
1e5 20 15.55 3-stage 0.806 0.76% 0.034 0.034 94.1% 0.197 -1.49% 0.017 0.017 94.2%
CMLE 0.799 -0.14% 0.033 0.034 94.9% 0.201 0.28% 0.017 0.017 95.2%
1e5 50 4.51 3-stage 0.818 2.21% 0.038 0.037 91.9% 0.197 -1.62% 0.008 0.008 93.2%
CMLE 0.801 0.11% 0.036 0.036 95.3% 0.200 0.02% 0.007 0.007 94.6%
Table 3: Simulation results for estimating the confounding bias parameter γ = 0.2 and the ETT
β = 0.8 under Gaussian mixture error based on 1000 replicates. See the caption of Table 1 for
description of the summary statistics.
n ηz βˆ Bias SE SD Cover γˆ Bias SE SD Cover
0.10 0.771 −3.64% 0.373 0.195 75.6% 0.256 27.78% 0.314 0.211 66.7%
1e4 0.25 0.798 −0.29% 0.056 0.059 93.9% 0.205 2.39% 0.044 0.049 91.4%
0.50 0.799 −0.12% 0.039 0.039 95.9% 0.201 0.69% 0.026 0.026 96.0%
0.10 0.780 −2.54% 0.106 0.084 77.0% 0.230 14.95% 0.090 0.101 69.2%
3e4 0.25 0.799 −0.09% 0.032 0.033 95.1% 0.202 0.80% 0.025 0.027 92.9%
0.50 0.799 −0.07% 0.023 0.022 95.4% 0.201 0.36% 0.015 0.015 95.8%
0.10 0.793 −0.86% 0.031 0.041 78.0% 0.210 4.96% 0.026 0.052 69.5%
1e5 0.25 0.800 0.03% 0.018 0.018 94.7% 0.200 0.24% 0.014 0.015 93.5%
0.50 0.800 0.03% 0.012 0.012 95.3% 0.200 0.14% 0.008 0.008 95.6%
simulations for the mixture model were only performed in the single IV case in which case the
approach appeared to become unreliable in the weak single IV setting, we expect the CMLE under
mixture Gaussian error will exhibit similar robustness in many weak IV regimes as the simple
Gaussian model explored in the previous simulation study.
4 An Application to the Large-Scale UK Biobank Study
Data
UK Biobank is a large-scale ongoing prospective cohort study that recruited around 500,000 partici-
pants aged 40-69 in 2006-2010. Participants provided biological samples, completed questionnaires,
underwent assessments, and had nurse led interviews. Follow up is chiefly through cohort-wide
linkages to National Health Service data, including electronic, coded death certificate, hospital,
and primary care data (Sudlow et al. 2015). To control for population stratification, we restricted
our analysis to participants with self-reported and genetically validated white British ancestry. For
quality control, we also excluded participants with (1) excess relatedness (more than 10 putative
third-degree relatives) or (2) mismatched information on sex between genotyping and self-report,
or (3) sex-chromosomes not XX or XY, or (4) poor-quality genotyping based on heterozygosity and
missing rates > 2%.
To illustrate our methods, we extracted a total of 289,010 white British subjects from the UK
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Table 4: Simulation results for estimating the confounding bias parameter γ = 0.2 and the ETT β = 0.8
under uniform mixture error based on 1000 replicates. See the caption of Table 1 for description of
the summary statistics.
n ηz βˆ Bias SE SD Cover γˆ Bias SE SD Cover
1e4 0.25 0.779 −2.65% 0.515 0.125 98.0% 0.235 17.52% 0.479 0.113 97.5%
0.50 0.800 −0.02% 0.047 0.052 92.9% 0.184 −7.84% 0.033 0.028 92.7%
3e4 0.25 0.793 −0.92% 0.069 0.067 98.6% 0.208 4.08% 0.057 0.046 98.2%
0.50 0.800 −0.01% 0.027 0.030 92.6% 0.182 −8.98% 0.019 0.016 85.1%
1e5† 0.25 0.799 −0.12% 0.032 0.036 94.2% 0.197 −1.72% 0.026 0.021 98.6%
0.50 0.801 0.10% 0.014 0.016 92.3% 0.181 -9.46% 0.010 0.008 55.2%
†: excludes 1 simulation replicate in which the Gaussian mixture procedure did not converge.
Biobank data with complete measurements in body mass index (BMI) and glucose levels. We
further selected BMI associated SNP potential IVs among the list provided by Sun et al. (2019).
We found 7 SNPs (in Table 5) that are predictive of the residual variance of glucose levels in
our Stage 2 regression (p < 0.01 ). The average BMI is 27.39 kg/m2 (SD: 4.75 kg/m2), and
the average glucose level is 5.12 mmol/L (SD: 1.21 mmol/L). We applied the proposed methods
to these data with the goal of evaluating the causal relationship between BMI as treatment and
glucose as outcome; analysis results are summarized in Table 5. For comparison purposes, we also
include results for standard two-stage least square method implemented in the R package ivreg (Fox
et al. 2020). The allele score for the 7 SNPs selected is defined as the signed sum of their minor
alleles, where the sign is determined by the regression coefficient in our stage 2 regression. We also
implemented MR-GENIUS method (Tchetgen Tchetgen et al. 2020) using the same 7 SNPs, the
causal effect of BMI on glucose was estimated as 0.046 (se: 0.01, p-value: 2.24 × 10−6). Crude
regression analysis by simply regressing glucose on BMI gives an estimate of 0.041 (se: 4.65×10−4,
p-value: < 2×10−16). Further, we included all 7 SNPs into a conventional regression together with
BMI, and obtained a similar estimate 0.039 (se: 4.65×10−4, p-value: < 2×10−16). It is interesting
to consider results obtained by selecting each SNP as single candidate IV as summarized in the
table. For instance, take the SNP rs2176040, the corresponding causal effect estimate is βˆ = 0.041
(se: 0.0139, p-value: 0.003), and the selection bias parameter is estimated as γˆ : 0.059(se:0.0098,
p-value: 2.93× 10−9). However, the standard two-stage least squares (TSLS) method gives causal
effect estimate −1.619(se: 2.04, p-value: 0.428). These conflicting inferences may be due to SNP
rs2176040 being an invalid IV, in which case TSLS likely yields biased results. We further combine
20 SNPs, 13 of them are weakly associated with the residual variance of glucose levels, we obtain
using MLE a causal effect estimate of BMI on glucose βˆ = 0.028 (se:0.0025, p-value:6.87× 10−31),
and a selection bias estimate of γˆ = 0.009 (se: 0.0017, p-value: 2.82 × 10−7). This final analysis
suggests a somewhat smaller treatment effect size than all other MR methods, while providing
strong statistical evidence of a positive effect with a relatively small but statistically significant
amount of confounding bias detected.
5 Discussion
In this paper, we have considered identification and inference about a causal effect in an observa-
tional study using a novel MR approach. MR MiSTERI leverages a possible association between
candidate IV SNPs and the variance of the outcome in order to disentangle confounding bias from
the causal effect of interest. Importantly, MR MiSTERI can recover unbiased inferences about the
causal effect in view even when none of the candidate IV SNPs is a valid IV. Key assumptions
which the approach relies on include no additive interaction involving a candidate IV SNP and the
treatment causal effect in the outcome model, and a requirement that the amount of selection bias
(measured on the odds ratio scale) remains constant as a function of SNP values. Violation of either
assumption may result in incorrect inferences about treatment effect. Although not pursued in this
paper, robustness to such violation may be assessed via a sensitivity analysis in which the impact
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Table 5: UK Biobank data analysis results. Columns 2-5 contain the results based on the model (1),
columns 6-9 contain results based on the Gaussian mixture model described in Section 2.4, columns
10-11 contain results using the standard two-stage least squares using the R package ivreg.
SNP βˆ se(βˆ) γˆ se(γˆ) βˆ∗ se(βˆ∗) γˆ∗ se(γˆ∗) βˆ∗∗ se(βˆ∗∗)
rs3736485 0.041 0.013 0.0001 0.0094 0.027 0.001 0.0031 0.0002 0.200 0.068
rs1558902 0.023 0.006 0.0128 0.0046 0.040 0.001 0.0025 0.0002 0.064 0.009
rs1808579 0.041 0.014 0.0001 0.0098 0.026 0.001 0.0042 0.0002 0.107 0.038
rs13021737 0.051 0.012 -0.0065 0.0084 0.036 0.001 -0.0043 0.0005 0.030 0.016
rs2176040 0.041 0.014 0.0585 0.0099 0.026 0.001 0.0009 0.0003 -1.619 2.041
rs10968576 0.047 0.016 -0.0040 0.0111 0.046 0.001 -0.0005 0.0004 0.079 0.025
rs10132280 0.030 0.013 0.0081 0.0094 0.062 0.004 -0.0228 0.0005 0.049 0.029
Allele score 0.030 0.003 0.0078 0.0021 0.033 0.005 0.0105 0.0002 0.089 0.009
of various departures from the assumption may be explored by varying sensitivity parameters. Al-
ternatively, as illustrated in our application, providing inferences using a variety of MR methods
each of which relying on a different set of assumptions provides a robustness check of empirical
findings relative to underlying assumptions needed for a causal interpretation of results. A notable
robustness property of the MLE approach to MR MiSTERI is that as we formally establish, it is
robust to many weak IV bias, thus providing certain theoretical guarantees of reliable performance
in many common MR settings where one might have available a relatively large number of weak
candidate IVs, many of which may be subject to pleiotropy. While the proposed methods require
correctly specified a Gaussian model for the conditional distribution of Y given A and Z, such an
assumption can be relaxed. In fact, in the paper, We also consider a Gaussian mixture model as
a framework to assess and possibly correct for possible violation of this assumption. Furthermore,
in the Supplementary Materials, we briefly describe a semiparametric three-stage estimation ap-
proach under the location-scale model which allows the distribution of standardized residuals to
remain unrestricted. It will be of interest to investigate robustness and efficiency properties of this
more flexible estimator, which we plan to pursue in future work. It would likewise be of interest
to investigate whether the proposed methods can be extended to the important setting of a binary
outcome, which is of common occurrence in epidemiology and other health and social sciences.
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Supplementary Materials
Proof of Theorem 1
Proof. Under assumptions (B1) - (B3), we have
D(Z = z) = E(Y | A = 1, Z = z)− E(Y | A = 0, Z = z) = β + γσ2(z). (S1)
Hence, we have the following two equations
D(Z = 1) = β + γσ2(Z = 1)
D(Z = 0) = β + γσ2(Z = 0).
Solving these two equations simultaneously gives the result in Theorem 1.
Estimation and Inference under Weak Identification
Consider the normal model (1). Let
In(Θ) = −E
{
∂2
∂Θ∂ΘT
ln(Θ)
}
be the Fisher information matrix for a sample of size n, λmin{In(Θ)} be the minimum eigenvalue
of In(Θ), tr(A) be the trace of a square matrix A.
Condition 2 summaries the regulaty conditions.
Condition 2 (Regularity Conditions). For every o = (y, a, z) in the support of O = (Y,A,Z), the
likelihood function denoted by f(Θ; o) is twice continuously differentiable in Θ and satisfies
∂
∂Θ
∫
ψΘ(o)dν =
∫
∂
∂Θ
ψΘ(o)dν
for ψΘ(o) = fΘ(o) and = ∂fΘ(o)/∂Θ, where ν is a suitable measure; there is a positive  such that
the Fisher information matrix In(Γ) is positive definite for Γ : ‖Γ−Θ‖ < ; and for any given Θ,
there exists a positive number  and a positive integrable function h, such that
sup
Γ:‖Γ−Θ‖<
∥∥∥∥∂2 log fΓ(o)∂Γ∂ΓT
∥∥∥∥ ≤ h(o)
for all o in the support of O, where ‖A‖ = √tr(ATA) for any matrix A.
Theorem 3 establishes the consistency and asymptotic normality of solutions to the score func-
tion.
Theorem 3. (a) Under Condition 2 and assume that the observed data Oi, i = 1, . . . , n are in-
dependent and identically distributed, if k/[λmin{nI1(Θ)}] → 0, then the sequence of conditional
maximum likelihood estimators {Θˆn} is consistent, i.e., Θˆn p−→ Θ.
(b) Any consistent sequence Θ˜n such that Sn(Θ˜) = 0 is asymptotically normal, and as n→∞,
√
n(Θ˜−Θ) d−→ N(0, {I1(Θ)}−1). (S2)
In fact, the general consistency condition in Theorem 3 can be written as λmin{nI1(Θ)} → ∞
and
tr
[
I−1n (Θ)E{Sn(Θ)Sn(Θ)T }
]
λmin{nI1(Θ)} → 0 (S3)
for general likelihood-based methods, which, for example, applies to the profile-likelihood esti-
mator in Zhao et al. (2019b). Specifically, in Zhao et al. (2019b), in their notations, k = 1,
E{Sn(Θ)Sn(Θ)T } = V1, In(Θ) = V2, and V1 = V2 + O(p), V2  n‖γ‖2, and thus, condition (S3)
2
becomes V1/V
2
2 = O{p/(n2‖γ‖4)} → 0, which is the condition for consistency in Zhao et al. (2019b,
Theorem 3.1).
Proof. First, notice that the condition k/[λmin{nI1(Θ)}] → 0 implies λmin{nI1(Θ)} → ∞. Let
Bn(c) = {Γ : ‖[In(Θ)]1/2(Γ−Θ)‖ ≤ c} for c > 0, where ‖A‖ =
√
tr(ATA) for any matrix A. Since
Bn(c) shrinks to Θ as n → ∞, the consistency result in Theorem 3(a) is implied by the fact that
for any  > 0, there exists c > 0 and n0 > 1 such that
P (ln(Γ)− ln(Θ) < 0 for all Γ ∈ ∂Bn(c)) ≥ 1− , n ≥ n0 (S4)
and Θˆn is unique for n ≥ n0, where ∂Bn(c) is the boundary of Bn(c). For Γ ∈ ∂Bn(c), the Taylor
expansion gives
ln(Γ)− ln(Θ) = cλT [In(Θ)]−1/2Sn(Θ)
+ (c2/2)λT [In(Θ)]
−1/2in(Γ∗)[In(Θ)]−1/2λ,
where λ = [In(Θ)]
1/2(Γ−Θ)/c satisfying ‖λ‖ = 1, in(Γ) = ∂2ln(Γ)/∂Γ∂ΓT , and Γ∗ lies between Γ
and Θ. Note that
E
‖in(Γ∗)− in(Θ)‖
n
≤ E max
Γ∈Bn(c)
‖in(Γ)− in(Θ)‖
n
≤ E max
Γ∈Bn(c)
‖i1(Γ)− i1(Θ)‖ → 0 (S5)
which follows from the dominated convergence theorem combined with the facts that (a) i1(Γ) =
∂l1(Γ)/∂Γ∂Γ
T is continuous in a neighborhood of Θ for any fixed observation; (b) Bn(c) shrinks to
{Θ} from λmin(In(Θ))→∞; and (c) for sufficiently large n, maxΓ∈Bn(c) ‖i1(Γ)− i1(Θ)‖ is bounded
by an integrate function under Condition 2. By the strong law of large numbers, ‖n−1in(Θ) +
I1(Θ)‖ a.s.−−→ 0. These results imply that
ln(Γ)− ln(Θ) = cλT [In(Θ)]−1/2Sn(Θ)− (1 + op(1))c2/2. (S6)
Note that maxλ{λT [In(Θ)]−1/2Sn(Θ)} = ‖In(Θ)−1/2Sn(Θ)‖ with
λ = In(Θ)
−1/2Sn(Θ)/‖In(Θ)−1/2Sn(Θ)‖.
Therefore, (S4) follows from (S6) and
P (cλT [In(Θ)]
−1/2Sn(Θ)− c2/2 < 0 for all λ s.t. ‖λ‖ = 1)
=P
(
max
λ
λT [In(Θ)]
−1/2Sn(Θ) < c/2
)
=P
(
‖In(Θ)−1/2Sn(Θ)‖ < c/2
)
=1− P
(
‖In(Θ)−1/2Sn(Θ)‖ ≥ c/2
)
≥1− 4E‖In(Θ)
−1/2Sn(Θ)‖2
c2/4
(from the Markov inequality)
=1− E tr{Sn(Θ)
T In(Θ)
−1Sn(Θ)}
c2/4
=1− tr{In(Θ)
−1E[Sn(Θ)STn (Θ)]}
c2/4
≥1− ,
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from choosing c such that c2/tr{In(Θ)−1E[Sn(Θ)STn (Θ)]} is large enough, which is possible because
c2/tr{In(Θ)−1E[Sn(Θ)STn (Θ)]}
≥‖[In(Θ)]1/2(Γ−Θ)‖2/tr{In(Θ)−1E[Sn(Θ)STn (Θ)]}
≥λmin[In(Θ)]‖Γ−Θ‖2/tr{In(Θ)−1E[Sn(Θ)STn (Θ)]}
=‖Γ−Θ‖2/o(1).
For n ≥ n0, Θˆn is unique because from Condition 2, the Fisher information In(Γ) is positive definite
in a neighborhood of Θ.
(b) Using the mean value theorem for vector-valued functions, we obtain that
−Sn(Θ) =
[∫ 1
0
in
(
Θ + t(Θ˜−Θ))dt] (Θˆ−Θ).
Note that using a similar argument as in (S5), when Θˆ−Θ = op(1),
1
n
∥∥∥in(Θ + t(Θ˜−Θ))− in(Θ)∥∥∥ p−→ 0.
Since n−1in(Θ)
p−→ −I1(Θ) and In(Θ) = nI1(Θ),
−Sn(Θ) = −In(Θ)(Θ˜−Θ) + op(‖In(Θ)(Θ˜−Θ)‖).
This and Slutsky’s theorem imply that
√
n(Θ˜−Θ) is asymptotically equivalent with
√
n[In(Θ)]
−1Sn(Θ) = n−1/2[I1(Θ)]−1Sn(Θ)
d−→ Nk(0, I[1(Θ)]−1)
by the central limit theorem for i.i.d. samples.
Estimation method under Gaussian mixture error
We describe the alternating optimization procedure with user-specified K and parametric models
σ(Z = z; η) and E(Y |A = 0, Z = z; θ) ≡ µ0(z; θ) indexed by finite-dimensional parameters η and θ
respectively.
(i) Initialization step: maximize the standard Gaussian location scale model
Y − {βA+ γAσ2 (Z; η) + µ0(Z; θ)}
σ (Z; η)
∼ N (0, 1)
with respect to (β, θ, η, γ) by maximum likelihood estimation, to obtain (β˜, θ˜, η˜, γ˜). Construct
the standardized residuals
˜ =
Y − {β˜A+ γ˜Aσ2 (Z; η˜) + µ0(Z; θ˜)}
σ (Z; η˜)
.
(ii) Maximize the Gaussian mixture location scale model
˜ ∼
K∑
k=1
pikN
(
µk, δ
2
k
)
with respect to (pi1, ..., piK , µ1, ..., µK , δ1, ..., δK) using constrained maximum likelihood esti-
mation to obtain (p˜i1, ..., p˜iK , µ˜1, ..., µ˜K , δ˜1, ..., δ˜K). Construct
v˜ = A
K∑
k=1
p˜ikω˜k δ˜
2
kσ
2 (Z; η˜)∑K
k=1 p˜ikω˜k
, w˜ =
σ (Z; η˜)∑K
k=1 p˜ikω˜k
{[
K∑
k=1
p˜ikω˜kµ˜k
]}
,
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where
ω˜k = exp{γ˜Aσ (Z; η˜) µ˜k + δ˜2k [γ˜Aσ (Z; η˜)]2 /2}.
(iii) Minimize n−1
∑
i{Yi − βAi − µ0(Zi; θ) − γv˜i − w˜i}2 using the least squares method with
offset w˜ to obtain new (β˜, θ˜, γ˜), followed by regressing the squared residuals to obtain new η˜.
Construct the standardized residuals
˜ =
Y − {β˜A+ µ0(Z; θ˜) + γ˜v˜ + w˜}
σ (Z; η˜)
,
based on the new values (β˜, θ˜, γ˜, η˜).
(iv) Iterate between steps (ii) and (iii) until change in log-likelihood derived at step (ii) falls below a
user-specified tolerance level. In this simulation we iterate until | logLLj−logLLj−1|/| logLLj−1| <
0.001 at the j-th iteration.
Asymptotic variance is estimated based on standard M-estimation theory by stacking the estimating
functions in steps (ii) and (iii), evaluated at the final parameter values at convergence.
Semiparametric three-stage estimation
Consider the general location-scale model
Y = E(Y |A,Z) + σ(Z) ≡ µ(A,Z) + σ(Z),
where  ⊥ A,Z. Under assumptions (B1)-(B3), the conditional mean function is given by
µ(a, z) = βa+ µ(0, z) +
∂
∂(γa)
lnE{exp (γaσ (z) ) |A = 0, Z = z}
= βa+ µ(0, z) + σ (z)
E { exp (γaσ (z) )}
E {exp (γaσ (z) )} .
A semiparametric three-stage estimator of (β, γ) may be implemented via the following steps:
(i) Fit the regression model µ(a, z) = ma (a)+mz (z)+maz (a, z), where 0 = mz (0) = maz (a, 0) =
maz (0, z) for identification, using a nonparametric method such as generalized additive model.
For example, if the support of Z is {0, 1, 2}, then the nonparametric model for the outcome is
of the form µ(a, z) = ma (a)+{γ1z+γ2z2}+{zm1 (a)+z2m2 (a)} with m1 (0) = m2 (0) = 0;
a saturated model may be considered if A also has finite support. Let µ̂ (a, z) denote the
resulting estimator of the mean µ(a, z).
(ii) Using the residuals from (i), fit a nonparametric model for the conditional variance σ2 (z). If
the support of Z is {0, 1, 2}, then we can specify the saturated model σ2(z) = exp(η0 + η1z+
η2z
2). Let σ̂2 (z) denote the resulting estimator of σ2(z).
(iii) Define ̂j = {Yj − µ̂ (Aj , Zj)} /σ̂ (Zj) and let
ĝi (γ) =
∑n
j=1 ̂j exp (γAiσ̂ (Zi) ̂j)∑n
j=1 exp (γAiσ̂ (Zi) ̂j)
, i = 1, ..., n.
The proposed semiparametric three-stage estimator of (β, γ) is
(βˆ, γˆ) = arg min
β,γ
∑
i
{Yi − βAi − µ̂(0, Zi)− σ̂ (Zi) ĝi (γ)}2 .
We note that a potentially more efficient approach is to maximize the log-likelihood for the model
using a kernel estimator for the density of standardized residuals from step (iii). Specifically, let
δ̂i(β, γ) = {Yj − βAi − µ̂(0, Zi)− σ̂ (Zi) ĝi (γ)}/σ̂ (Zi)
5
and define
`n(β, γ) =
n∑
i=1
log f̂h(δ̂i(β, γ)),
where f̂h() =
1
nh
∑n
i=1K
(
−̂i
h
)
is a kernel density estimator with bandwidth h > 0. The alterna-
tive estimator of (β, γ) is given by
(βˆ, γˆ) = arg max
β,γ
{`n(β, γ)} .
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